rs140291094
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_145064.3(STAC3):c.851G>C(p.Trp284Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000644 in 1,614,214 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_145064.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
STAC3 | NM_145064.3 | c.851G>C | p.Trp284Ser | missense_variant | 10/12 | ENST00000332782.7 | NP_659501.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
STAC3 | ENST00000332782.7 | c.851G>C | p.Trp284Ser | missense_variant | 10/12 | 2 | NM_145064.3 | ENSP00000329200.2 | ||
STAC3 | ENST00000554578.5 | c.734G>C | p.Trp245Ser | missense_variant | 9/11 | 1 | ENSP00000452068.1 | |||
STAC3 | ENST00000557176.5 | n.226G>C | non_coding_transcript_exon_variant | 6/8 | 1 | ENSP00000450740.1 | ||||
STAC3 | ENST00000546246.2 | c.293G>C | p.Trp98Ser | missense_variant | 7/9 | 2 | ENSP00000441515.2 |
Frequencies
GnomAD3 genomes AF: 0.000335 AC: 51AN: 152246Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000915 AC: 23AN: 251398Hom.: 0 AF XY: 0.0000810 AC XY: 11AN XY: 135870
GnomAD4 exome AF: 0.0000369 AC: 54AN: 1461850Hom.: 0 Cov.: 33 AF XY: 0.0000303 AC XY: 22AN XY: 727226
GnomAD4 genome AF: 0.000328 AC: 50AN: 152364Hom.: 0 Cov.: 32 AF XY: 0.000336 AC XY: 25AN XY: 74498
ClinVar
Submissions by phenotype
Bailey-Bloch congenital myopathy Pathogenic:14Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 19, 2023 | This sequence change replaces tryptophan, which is neutral and slightly polar, with serine, which is neutral and polar, at codon 284 of the STAC3 protein (p.Trp284Ser). This variant is present in population databases (rs140291094, gnomAD 0.1%). This missense change has been observed in individual(s) with Native American myopathy, Carey–Fineman–Ziter syndrome and Moebius syndrome (PMID: 23736855, 28777491). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 88744). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt STAC3 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects STAC3 function (PMID: 23736855). For these reasons, this variant has been classified as Pathogenic. - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jan 13, 2021 | - - |
Pathogenic, criteria provided, single submitter | research | Al Jalila Children’s Genomics Center, Al Jalila Childrens Speciality Hospital | Oct 04, 2024 | PM3,PP1,PM2,PP3 - |
Likely pathogenic, criteria provided, single submitter | research | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Mar 17, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego | - | This variant has been previously reported as a compound heterozygous and homozygous change in individuals with Bailey-Bloch congenital myopathy (PMID: 30168660, 23736855, 27621462, 28777491, 28003463). Functional studies have shown this variant impairs normal STAC3 protein function (PMID: 23736855). The c.851G>C (p.Trp284Ser) variant is present in the heterozygous state in the gnomAD population database at a frequency of 0.00012% (33/282798). It affects a highly conserved amino acid and is predicted by multiple in silico tools to have a deleterious effect on protein function. Based on the available evidence, the c.851G>C (p.Trp284Ser) variant is classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Laboratoire Génétique Moléculaire, CHRU TOURS | May 23, 2022 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 2013 | - - |
Pathogenic, criteria provided, single submitter | research | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jun 15, 2018 | The homozygous p.Trp284Ser variant was identified by our study in one individual with Native American myopathy. This variant is pathogenic based on multiple reports in ClinVar and the literature. - |
Pathogenic, criteria provided, single submitter | clinical testing | Centogene AG - the Rare Disease Company | Oct 27, 2020 | - - |
Pathogenic, criteria provided, single submitter | research | Baylor-Hopkins Center for Mendelian Genomics, Johns Hopkins University School of Medicine | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 05, 2022 | Variant summary: STAC3 c.851G>C (p.Trp284Ser) results in a non-conservative amino acid change located in the SH3 domain (IPR001452) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 9.1e-05 in 251398 control chromosomes, predominantly at a frequency of 0.0011 within the African or African-American subpopulation in the gnomAD database. c.851G>C has been reported in the literature as a biallelic genotype in multiple individuals affected with Bailey-Bloch Congenital Myopathy and has been found to segregrate with the disease phenotype in multiple families affected with the disorder (e.g. Horstick_2013, Telegrafi_2017, Zaharieva_2018). These data indicate that the variant is very likely to be associated with disease. At least one experimental study examining the effect of the variant protein in a zebrafish model system found that it diminished excitation-contraction coupling in fast twitch muscle, suggesting that the variant affects normal protein function (e.g. Horstick_2013). Ten submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Jan 03, 2022 | The variant has been observed in multiple (>3) similarly affected unrelated individuals (PMID: 28777491, 23736855, PS4_S). The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least one similarly affected unrelated individual (PMID: 28777491, PM3_M) and co-segregated with Myopathy, congenital, Baily-Bloch in multiple affected family members (PMID: 28777491, PP1_P). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.886, 3CNET: 0.861, PP3_P). It is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.000117, PM2_M). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, criteria provided, single submitter | research | Division of Human Genetics, National Health Laboratory Service/University of the Witwatersrand | Jul 01, 2023 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 22, 2022 | Published functional studies demonstrate a damaging effect (reduction of amount, organization, stability, and voltage sensitivity of calcium channels) (Linsley et al., 2017; Horstick et al., 2013); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 28003463, 27621462, 28777491, 28676249, 29078335, 23736855, 30168660, 30872186, 34374989, 35205385, 35912995, 35481653, 34208776, 33827624, 33060286) - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2019 | - - |
STAC3-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 24, 2024 | The STAC3 c.851G>C variant is predicted to result in the amino acid substitution p.Trp284Ser. This variant has been reported in the homozygous and compound heterozygous states to be causative for congenital Bailey-Bloch myopathy with susceptibility to malignant hyperthermia (Stamm et al. 2008. PubMed ID: 18553514; Horstick et al. 2013. PubMed ID: 23736855; Telegrafi et al. 2017. PubMed ID: 28777491; Schoonen et al. 2019. PubMed ID: 30872186). This variant is reported in 0.10% of alleles in individuals of African descent in gnomAD. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at